CSL, the Australian biotechnology company behind CSL Behring in King of Prussia, plans to cut up to 15 percent of its global workforce, or about 3,000 jobs worldwide, writes John George for the Philadelphia Business Journal.
The cost-cutting initiative is part of a broader strategy that includes spinning off its vaccine business.
It is still unknown how many employees will be affected at CSL Behring, which has around 1,000 workers at its Gulph Road headquarters and a nearby First Avenue office.
CSL Behring, with operations in 30 countries, is a biopharmaceutical firm focusing on plasma-derived and recombinant therapies targeting rare and serious medical conditions.
As part of the restructuring, CSL will reduce its global research and development operations from 11 hubs to six, merge the medical and commercial functions of CSL Behring and CSL Vifor, and close 22 underperforming plasma collection centers across the United States, including locations in Lindenwold and Brooklawn, New Jersey.
CSL officials cited several challenging factors influencing their restructuring plans, including a “dynamic geopolitical backdrop,” increasing competitive pressure, and the company’s organizational complexity.
Read more about CSL Behring and the reason for its recent job cuts in the Philadelphia Business Journal.
_____
